ketoconazole has been researched along with Liver Diseases in 18 studies
1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine : A dioxolane that is 1,3-dioxolane which is substituted at positions 2, 2, and 4 by imidazol-1-ylmethyl, 2,4-dichlorophenyl, and [para-(4-acetylpiperazin-1-yl)phenoxy]methyl groups, respectively.
Liver Diseases: Pathological processes of the LIVER.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The case of a patient with environmental illness and systemic candidiasis for six weeks with ketoconazole, liver enzyme concentrations increased." | 8.78 | Ketoconazole hepatotoxicity in a patient treated for environmental illness and systemic candidiasis. ( Brusko, CS; Marten, JT, 1991) |
| " The first was a case of ketoconazole-induced hepatitis, and the second was a case of hepatitis C-related liver cirrhosis with hepatocellular carcinoma." | 7.71 | Ranitidine-related Stevens-Johnson syndrome in patients with severe liver diseases: a report of two cases. ( Chang, FY; Huang, DF; Huang, YH; Huang, YS; Huo, TI; Lee, SD; Lin, CC; Wu, JC, 2001) |
| " violaceum tinea capitis was given systemic ketoconazole therapy." | 7.68 | Juvenile tinea capitis caused by Trichophyton violaceum. Hepatic reactions during ketoconazole treatment. ( Falk, ES; Gasior-Chrzan, B; Stenvold, SE, 1991) |
| "Pretreatment with ketoconazole for 48 hr completely abolished the protective effect of a subsequent therapy with amphotericin B, whether ketoconazole therapy was stopped (P less than ." | 5.27 | The effect of ketoconazole on amphotericin B in a model of disseminated aspergillosis. ( Frick, PG; Schaffner, A, 1985) |
| " The case of a patient with environmental illness and systemic candidiasis for six weeks with ketoconazole, liver enzyme concentrations increased." | 4.78 | Ketoconazole hepatotoxicity in a patient treated for environmental illness and systemic candidiasis. ( Brusko, CS; Marten, JT, 1991) |
| " The first was a case of ketoconazole-induced hepatitis, and the second was a case of hepatitis C-related liver cirrhosis with hepatocellular carcinoma." | 3.71 | Ranitidine-related Stevens-Johnson syndrome in patients with severe liver diseases: a report of two cases. ( Chang, FY; Huang, DF; Huang, YH; Huang, YS; Huo, TI; Lee, SD; Lin, CC; Wu, JC, 2001) |
| " violaceum tinea capitis was given systemic ketoconazole therapy." | 3.68 | Juvenile tinea capitis caused by Trichophyton violaceum. Hepatic reactions during ketoconazole treatment. ( Falk, ES; Gasior-Chrzan, B; Stenvold, SE, 1991) |
| " The aim of this study was to establish a physiologically based pharmacokinetic (PBPK) model to elucidate in detail the pharmacokinetics of teneligliptin." | 2.80 | Human pharmacokinetic profiling of the dipeptidyl peptidase-IV inhibitor teneligliptin using physiologically based pharmacokinetic modeling. ( Emoto, C; Nakamaru, Y; Shimizu, M; Yamazaki, H, 2015) |
| " Ten pharmacokinetic studies and three efficacy/safety studies in overactive bladder (OAB) patients were pooled for the population pharmacokinetic analysis." | 2.79 | Population pharmacokinetics of the 5-hydroxymethyl metabolite of tolterodine after administration of fesoterodine sustained release tablet in Western and East Asian populations. ( Malhotra, B; Oishi, M; Tomono, Y; Yamagami, H, 2014) |
| "Rivaroxaban is a direct oral anticoagulant with a large inter-individual variability." | 1.48 | Application of physiologically based pharmacokinetic modeling to the prediction of drug-drug and drug-disease interactions for rivaroxaban. ( Ge, W; Jiang, Q; Xu, R, 2018) |
| "Ketoconazole has only recently been recognized as a cause of hepatic injury, with most reports coming from outside the United States." | 1.27 | Hepatic injury associated with ketoconazole therapy. Analysis of 33 cases. ( Benson, GD; Ishak, KG; Lewis, JH; Zimmerman, HJ, 1984) |
| "Hepatic candidiasis has been increasingly recognized as a variant of disseminated candidiasis in immunocompromised patients." | 1.27 | Hepatic candidiasis: an increasing problem in immunocompromised patients. ( Feld, R; Haron, E; Hasselback, R; Matlow, A; Patterson, B; Tuffnell, P, 1987) |
| "Pretreatment with ketoconazole for 48 hr completely abolished the protective effect of a subsequent therapy with amphotericin B, whether ketoconazole therapy was stopped (P less than ." | 1.27 | The effect of ketoconazole on amphotericin B in a model of disseminated aspergillosis. ( Frick, PG; Schaffner, A, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (33.33) | 18.7374 |
| 1990's | 6 (33.33) | 18.2507 |
| 2000's | 1 (5.56) | 29.6817 |
| 2010's | 3 (16.67) | 24.3611 |
| 2020's | 2 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Jester, N | 1 |
| Kang, P | 1 |
| Steele, M | 1 |
| Howells, L | 1 |
| Santer, M | 1 |
| Sivyer, K | 1 |
| Lawton, S | 1 |
| Roberts, A | 1 |
| Teasdale, E | 1 |
| Muller, I | 1 |
| Greenwell, K | 1 |
| Silva, LP | 1 |
| Silva, TA | 1 |
| Moraes, FC | 1 |
| Fatibello-Filho, O | 1 |
| Durrani, TS | 1 |
| Farooqi, A | 1 |
| Zhang, J | 3 |
| Xu, C | 1 |
| Gao, L | 1 |
| Zhang, D | 1 |
| Li, C | 1 |
| Liu, J | 1 |
| Jiang, PP | 1 |
| Guo, YX | 1 |
| Yang, XL | 1 |
| Xu, J | 1 |
| Wang, D | 1 |
| Liu, P | 1 |
| Zhong, L | 1 |
| Huang, S | 1 |
| Gong, L | 1 |
| Han, D | 1 |
| Wang, S | 1 |
| Xiao, M | 1 |
| Meng, Y | 1 |
| Kraemer, R | 1 |
| Smith, HJ | 1 |
| Matthys, H | 1 |
| Xin, D | 1 |
| Bai, Y | 1 |
| Bi, Y | 1 |
| He, L | 1 |
| Kang, Y | 1 |
| Pan, C | 1 |
| Zhu, H | 1 |
| Chen, H | 1 |
| Qu, L | 1 |
| Lan, X | 1 |
| Tong, Y | 1 |
| Wang, L | 1 |
| Wang, Q | 1 |
| Huang, H | 1 |
| Chen, X | 1 |
| Zhang, Q | 1 |
| Li, H | 1 |
| Sun, N | 1 |
| Liu, G | 1 |
| Zhang, B | 1 |
| Song, F | 1 |
| Alterovitz, G | 1 |
| Dai, H | 1 |
| Zhang, L | 1 |
| Macho, LP | 1 |
| Center, SA | 1 |
| Randolph, JF | 1 |
| Dumars, LA | 1 |
| Rush, SE | 1 |
| Cameron, MK | 1 |
| Lucy, JM | 1 |
| Hall-Fonte, DL | 1 |
| McDonough, SP | 1 |
| Peters-Kennedy, J | 1 |
| Marinoff, J | 1 |
| Harrison, J | 1 |
| Sabatino, B | 1 |
| Deitz, K | 1 |
| Xu, R | 1 |
| Ge, W | 1 |
| Jiang, Q | 1 |
| Oishi, M | 1 |
| Tomono, Y | 1 |
| Yamagami, H | 1 |
| Malhotra, B | 1 |
| Nakamaru, Y | 1 |
| Emoto, C | 1 |
| Shimizu, M | 1 |
| Yamazaki, H | 1 |
| Kolts, BE | 1 |
| Langfitt, M | 1 |
| Brass, C | 1 |
| Galgiani, JN | 2 |
| Blaschke, TF | 1 |
| Defelice, R | 1 |
| O'Reilly, RA | 1 |
| Stevens, DA | 1 |
| Lewis, JH | 1 |
| Zimmerman, HJ | 1 |
| Benson, GD | 1 |
| Ishak, KG | 1 |
| Findor, JA | 1 |
| Sorda, JA | 1 |
| Igartua, EB | 1 |
| Avagnina, A | 1 |
| Lin, CC | 1 |
| Wu, JC | 1 |
| Huang, DF | 1 |
| Huang, YS | 1 |
| Huang, YH | 1 |
| Huo, TI | 1 |
| Chang, FY | 1 |
| Lee, SD | 1 |
| Lavrijsen, AP | 1 |
| Balmus, KJ | 1 |
| Nugteren-Huying, WM | 1 |
| Roldaan, AC | 1 |
| van't Wout, JW | 1 |
| Stricker, BH | 1 |
| Gasior-Chrzan, B | 1 |
| Stenvold, SE | 1 |
| Falk, ES | 1 |
| Brusko, CS | 1 |
| Marten, JT | 1 |
| Fish, DG | 1 |
| Ampel, NM | 1 |
| Dols, CL | 1 |
| Kelly, PC | 1 |
| Johnson, CH | 1 |
| Pappagianis, D | 1 |
| Edwards, JE | 1 |
| Wasserman, RB | 1 |
| Clark, RJ | 1 |
| Seebacher, C | 1 |
| Haron, E | 1 |
| Feld, R | 1 |
| Tuffnell, P | 1 |
| Patterson, B | 1 |
| Hasselback, R | 1 |
| Matlow, A | 1 |
| Schaffner, A | 1 |
| Frick, PG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Feedback Control of FSH Secretion in the Human Male[NCT00392457] | 175 participants (Anticipated) | Interventional | 1995-07-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for ketoconazole and Liver Diseases
| Article | Year |
|---|---|
Topics: Adult; Aged; Analgesics, Opioid; Anesthetics, Inhalation; Animals; Antifungal Agents; Antirheumatic | 2021 |
Ketoconazole hepatotoxicity in a patient treated for environmental illness and systemic candidiasis.
Topics: Adult; Candidiasis; Chemical and Drug Induced Liver Injury; Environmental Exposure; Environmental Po | 1991 |
3 trials available for ketoconazole and Liver Diseases
| Article | Year |
|---|---|
Topics: Adult; Aged; Analgesics, Opioid; Anesthetics, Inhalation; Animals; Antifungal Agents; Antirheumatic | 2021 |
Population pharmacokinetics of the 5-hydroxymethyl metabolite of tolterodine after administration of fesoterodine sustained release tablet in Western and East Asian populations.
Topics: Adult; Aged; Aged, 80 and over; Asian People; Benzhydryl Compounds; Creatinine; Cresols; Cytochrome | 2014 |
Human pharmacokinetic profiling of the dipeptidyl peptidase-IV inhibitor teneligliptin using physiologically based pharmacokinetic modeling.
Topics: Adult; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Dipeptidyl-Peptidase IV Inhibitors | 2015 |
14 other studies available for ketoconazole and Liver Diseases
| Article | Year |
|---|---|
Clinical, clinicopathologic, and hepatic histopathologic features associated with probable ketoconazole-induced liver injury in dogs: 15 cases (2015-2018).
Topics: Animals; Chemical and Drug Induced Liver Injury, Chronic; Dog Diseases; Dogs; Ketoconazole; Liver Di | 2020 |
Application of physiologically based pharmacokinetic modeling to the prediction of drug-drug and drug-disease interactions for rivaroxaban.
Topics: Adult; ATP Binding Cassette Transporter, Subfamily B, Member 1; Clarithromycin; Computer Simulation; | 2018 |
Drugs and the liver.
Topics: Acetaminophen; Adult; Aspirin; Chemical and Drug Induced Liver Injury; Chemical and Drug Induced Liv | 1984 |
Disposition of ketoconazole, an oral antifungal, in humans.
Topics: Administration, Oral; Adult; Antacids; Antifungal Agents; Child; Drug Interactions; Humans; Imidazol | 1982 |
Hepatic injury associated with ketoconazole therapy. Analysis of 33 cases.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Alkaline Phosphatase; Aspartate Aminotransferases; Ch | 1984 |
Ketoconazole-induced liver damage.
Topics: Adult; Aged; Antifungal Agents; Chemical and Drug Induced Liver Injury; Fatal Outcome; Female; Human | 1998 |
Ranitidine-related Stevens-Johnson syndrome in patients with severe liver diseases: a report of two cases.
Topics: Antifungal Agents; Carcinoma, Hepatocellular; Chemical and Drug Induced Liver Injury; Female; Hepati | 2001 |
Hepatic injury associated with itraconazole.
Topics: Aged; Antifungal Agents; Chemical and Drug Induced Liver Injury; Female; Humans; Itraconazole; Ketoc | 1992 |
Special drug communication teleconference. August 7, 1992.
Topics: Anti-Bacterial Agents; Arrhythmias, Cardiac; Astemizole; Contraindications; Drug Incompatibility; Dr | 1992 |
Juvenile tinea capitis caused by Trichophyton violaceum. Hepatic reactions during ketoconazole treatment.
Topics: Chemical and Drug Induced Liver Injury; Child; Clotrimazole; Humans; Ketoconazole; Liver Diseases; M | 1991 |
Coccidioidomycosis during human immunodeficiency virus infection. A review of 77 patients.
Topics: Adult; Amphotericin B; Arizona; California; Coccidioidomycosis; Dermatomycoses; Female; Follow-Up St | 1990 |
Comparison of benefit against risk of ketoconazole therapy.
Topics: Adult; Aged; Candidiasis; Chemical and Drug Induced Liver Injury; Clinical Enzyme Tests; Dermatomyco | 1986 |
Hepatic candidiasis: an increasing problem in immunocompromised patients.
Topics: Adult; Amphotericin B; Biopsy; Candida; Candidiasis; Drug Therapy, Combination; Female; Flucytosine; | 1987 |
The effect of ketoconazole on amphotericin B in a model of disseminated aspergillosis.
Topics: Amphotericin B; Animals; Aspergillosis; Disease Models, Animal; Female; Humans; In Vitro Techniques; | 1985 |